FDA to review Hospira's EPO biosimilar

Hospira Inc. (NYSE:HSP) said FDA accepted its BLA for Retacrit, a biosimilar of anemia drug Epogen epoetin alfa from Amgen Inc. (NASDAQ:AMGN)

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE